Ultragenyx Pharmaceutical has seen its stock retreat sharply over the past few years even as it secured full FDA approval for FAYUVI, a gene therapy for Sanfilippo syndrome Type A. That mix of regulatory progress and a battered share price puts the focus squarely on one question for investors who follow Ultragenyx: whether the current market value can be explained by its sales.
- Over the past 5 years, Ultragenyx Pharmaceutical’s share price has fallen 85.1%, which makes the current valuation debate tightly linked to what investors are willing to pay for its existing and potential revenue base.
- The recent FDA approval of FAYUVI may support expectations for future sales from gene therapies and influence how much investors are prepared to pay today for Ultragenyx Pharmaceutical’s top line.
- Your read on Ultragenyx Pharmaceutical is one view; the desks covering it have another. See what analysts think Ultragenyx Pharmaceutical's shares could be worth.
The issue now is whether Ultragenyx Pharmaceutical’s current share price is justified by its sales when set against the Fair Ratio benchmark.
If you want more ideas built around this kind of pressure test on revenues rather than story, a focused screen of 29 high quality undervalued stocks can be a useful second starting point for your research.
Is Ultragenyx Pharmaceutical Getting Expensive on Sales?
P/S works fairly well for Ultragenyx Pharmaceutical because the business is still loss making and investors are mostly paying for the revenue base and pipeline potential. The stock currently trades on a P/S of about 2.0x, which is far below the wider Biotechs industry average of roughly 12.4x and well under the peer group at about 19.7x.
Despite the recent FAYUVI approval sparking a sharp move in the share price, the current P/S still sits above the Fair Ratio that would be expected once growth prospects, margins and risk profile are taken into account. This points to the shares screening overvalued on this framework. That gap suggests buyers are already paying a premium on sales for Ultragenyx Pharmaceutical relative to what this model considers a balanced trade off between potential and risk, so you would need to be comfortable that the underlying economics can justify that premium. Explore the numbers behind Ultragenyx Pharmaceutical's P/S valuation.
The Ultragenyx Pharmaceutical Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Ultragenyx Pharmaceutical pick up where this valuation puzzle leaves off. They spell out which paths for revenue growth, profitability and earnings would need to play out for the stock to trade meaningfully higher or lower than today. Each narrative links its number to a specific view on how Ultragenyx Pharmaceutical's growth, margins and risks could evolve. This gives you something concrete to revisit as fresh information comes through.
One of the top community narratives on Ultragenyx Pharmaceutical: 44% undervalued
"Ultragenyx has phenomenal science, but its commercial execution is a cash-incinerating treadmill..."
Discover why this Narrative puts Ultragenyx Pharmaceutical at 44% undervalued.
Before moving on from Ultragenyx Pharmaceutical, there is one more piece of the puzzle
Market ratios tell you what investors are paying today. The next question is how professionals currently modelling Ultragenyx Pharmaceutical expect the business to look a few years from now. Explore where analysts expect Ultragenyx Pharmaceutical to be in a few years.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com